{"organizations": [], "uuid": "29f038e0011e2892ceabe5439be31f03928b6bc9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/05/08/the-associated-press-atara-biotherapeutics-1q-earnings-snapshot.html", "country": "US", "domain_rank": 767, "title": "Atara Biotherapeutics: 1Q Earnings Snapshot", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T15:28:00.000+03:00", "replies_count": 0, "uuid": "29f038e0011e2892ceabe5439be31f03928b6bc9"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/05/08/the-associated-press-atara-biotherapeutics-1q-earnings-snapshot.html", "ord_in_thread": 0, "title": "Atara Biotherapeutics: 1Q Earnings Snapshot", "locations": [], "entities": {"persons": [], "locations": [{"name": "san francisco", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "south san francisco", "sentiment": "none"}], "organizations": [{"name": "atara biotherapeutics", "sentiment": "negative"}, {"name": "atara biotherapeutics inc.", "sentiment": "negative"}, {"name": "atra", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Tuesday reported a loss of $41.8 million in its first quarter.\nThe South San Francisco, California-based company said it had a loss of $1.05 per share.\nThe results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 93 cents per share.\nAtara Biotherapeutics shares have more than doubled since the beginning of the year. The stock has nearly tripled in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on ATRA at https://www.zacks.com/ap/ATRA", "external_links": ["https://www.zacks.com/ap/ATRA", "http://automatedinsights.com/ap"], "published": "2018-05-08T15:28:00.000+03:00", "crawled": "2018-05-08T17:08:59.002+03:00", "highlightTitle": ""}